We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors.
- Authors
Dixon, J. Michael
- Abstract
This study analysed data after a median of 51 months follow-up from 4922 postmenopausal women with early hormone-sensitive breast cancer randomly assigned to 5 years of treatment with letrozole or tamoxifen. Tumors from 3650 (74%) patients were centrally assessed for estrogen receptor, progesterone receptor and ErbB2 status. By central assessment, 7% (257 of 3650) of tumors were classified as ErbB2-positive. Disease-free survival was significantly worse in patients with ErbB2-positive tumors (p < 0.0001). Letrozole improved disease-free survival compared with tamoxifen regardless of ErbB2 status.
- Subjects
OSTEOPOROSIS in women; BREAST cancer; TAMOXIFEN; PROGESTERONE receptors; SELECTIVE estrogen receptor modulators; AROMATASE
- Publication
Women's Health (17455057), 2008, Vol 4, Issue 3, p229
- ISSN
1745-5057
- Publication type
Article
- DOI
10.2217/17455057.4.3.229